PMID- 32547218
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 12
DP  - 2020
TI  - A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy 
      Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung 
      Cancer.
PG  - 3827-3834
LID - 10.2147/CMAR.S249678 [doi]
AB  - PURPOSE: Anlotinib is a newly developed oral multitarget tyrosine kinase 
      inhibitor. We retrospectively evaluated the toxicity and clinical efficacy of 
      chemotherapy combined with anlotinib versus chemotherapy alone for 
      metastatic/advanced non-small cell lung cancer (NSCLC) in patients who failed 
      first- or second-line systemic treatment in China. PATIENTS AND METHODS: In this 
      retrospective trial, ninety-four advanced NSCLC patients received chemotherapy 
      combined with anlotinib (n = 41) or chemotherapy alone (n = 53) in Henan Cancer 
      Hospital. We recorded the objective response rate (ORR), disease control rate 
      (DCR), progression-free survival (PFS) and adverse events (AEs). RESULTS: In the 
      anlotinib plus chemotherapy group, eleven patients (27%) achieved a PR (partial 
      response), and twenty-one patients (51%) achieved SD (stable disease), with an 
      ORR of 27% and a DCR of 78%. In the chemotherapy alone group, eight patients 
      (15%) achieved a PR, and nineteen patients (36%) had SD, with an ORR of 15% and a 
      DCR of 51%. The ORR in the combination arm was slightly, but not obviously, 
      higher than that in the chemotherapy arm (27% vs 15%, p > 0.05). In addition, the 
      DCR was significantly higher in the combination arm than in the chemotherapy 
      alone arm (78% vs 51%, p=0.007). At the end of follow-up, patients in the 
      combination arm had a 1.5-month longer median PFS than patients in the 
      chemotherapy arm; this difference was statistically significant (5.0 vs 3.5, 
      p=0.002). The median OS was not achieved at the final analysis. The hematological 
      and nonhematological toxicities were well tolerated and controlled. In general, 
      most toxicity was limited to grade I or II, well tolerated and controlled. 
      CONCLUSION: Our study suggests that anlotinib combined with chemotherapy may be 
      an effective and well-tolerated treatment for advanced NSCLC in patients who fail 
      first- or second-line therapy.
CI  - (c) 2020 Wang et al.
FAU - Wang, Hai-Ying
AU  - Wang HY
AD  - Department of Internal Medicine, Henan Cancer Hospital or Affiliated Cancer 
      Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
FAU - Chu, Jun-Feng
AU  - Chu JF
AD  - Department of Internal Medicine, Henan Cancer Hospital or Affiliated Cancer 
      Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
FAU - Zhao, Yan
AU  - Zhao Y
AD  - Department of Internal Medicine, Henan Cancer Hospital or Affiliated Cancer 
      Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
FAU - Tang, Hong
AU  - Tang H
AD  - Department of Internal Medicine, Henan Cancer Hospital or Affiliated Cancer 
      Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
FAU - Wang, Li-Li
AU  - Wang LL
AD  - Department of Internal Medicine, Henan Cancer Hospital or Affiliated Cancer 
      Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
FAU - Zhou, Meng-Qiang
AU  - Zhou MQ
AD  - Department of Internal Medicine, Henan Cancer Hospital or Affiliated Cancer 
      Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
FAU - Yan, Zheng
AU  - Yan Z
AD  - Department of Internal Medicine, Henan Cancer Hospital or Affiliated Cancer 
      Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
FAU - Liu, Yan-Yan
AU  - Liu YY
AD  - Department of Internal Medicine, Henan Cancer Hospital or Affiliated Cancer 
      Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
FAU - Yao, Zhi-Hua
AU  - Yao ZH
AD  - Department of Internal Medicine, Henan Cancer Hospital or Affiliated Cancer 
      Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20200522
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC7250176
OTO - NOTNLM
OT  - advanced non-small cell lung cancer
OT  - anlotinib
OT  - chemotherapy
OT  - efficacy
OT  - toxicity
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/06/18 06:00
MHDA- 2020/06/18 06:01
PMCR- 2020/05/22
CRDT- 2020/06/18 06:00
PHST- 2020/02/13 00:00 [received]
PHST- 2020/05/09 00:00 [accepted]
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/06/18 06:01 [medline]
PHST- 2020/05/22 00:00 [pmc-release]
AID - 249678 [pii]
AID - 10.2147/CMAR.S249678 [doi]
PST - epublish
SO  - Cancer Manag Res. 2020 May 22;12:3827-3834. doi: 10.2147/CMAR.S249678. 
      eCollection 2020.